Antitumoral analogs of lamellarins
CA 2493725 A1 · Owner: Pharma Mar, S.A.U. · Inventors: Francesch Solloso, Andres; Cuevas Marchante, Carmen; Bailly, Christian
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
New lamellarins are provided of the general formula III wherein X is selected from the group consisting of N, O and S; wherein R1 R2, R3, R4, R5, R6, R7, R8 and R9 are each independently selected from the group consisting of H OH, OR~, SH, SR~, SO2R~, NHR~, N(R~)2, N=R' NHCOR', N(COR~)2, NHS02R~, N02, PO(R~2 P02R', C(=0)H, C(=0)R', C02H, C02R~, OPO(R~)2 OP02R', OC(=0)H, OC(=0)R~, N=C(R')2, substituted or unsubstituted C1-C12 alkyl substituted or , unsubstituted C1-C12 haloalkyl substituted or unsubstituted C2-C12 alkenyl substituted or unsubstituted C2-C12 alkynyl substituted or unsubstituted , aryl, substituted or unsubstituted aralkyl and substituted or unsubstituted heteroaromatic; …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed August 13, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended August 13, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 13, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.